Free Trial

MediWound Q2 2024 Earnings Report

MediWound logo
$17.90 +0.63 (+3.65%)
(As of 02:08 PM ET)

MediWound EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

MediWound Revenue Results

Actual Revenue
$5.06 million
Expected Revenue
$5.07 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

MediWound Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

MediWound Earnings Headlines

Affordable AI Plays: 2 Stocks Under $10 with Huge Potential!
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
MediWound (NASDAQ:MDWD) Stock, Option Chain
MediWound Advances Enzymatic Therapeutics Amid Financial Shifts
Mediwound’s Promising Outlook: Expansion and Trials Support Buy Rating
See More MediWound Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediWound? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediWound and other key companies, straight to your email.

About MediWound

MediWound (NASDAQ:MDWD), a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

View MediWound Profile

More Earnings Resources from MarketBeat

Upcoming Earnings